Stifel raised the firm’s price target on Patterson-UTI (PTEN) to $9 from $8 and keeps a Buy rating on the shares after the company reported better-than-expected Q3 results and Q4 guidance above the firm’s pre-release forecast. Following the report, the firm is “modestly bumping our forecasts,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTEN: